194 related articles for article (PubMed ID: 8218121)
21. [Determination of the growth fraction using monoclonal antibody Ki-67 in breast cancers].
Lellé RJ; Heidenreich W; Borsi C; Stauch G; Gerdes J
J Gynecol Obstet Biol Reprod (Paris); 1988; 17(4):485-9. PubMed ID: 3209828
[TBL] [Abstract][Full Text] [Related]
22. Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.
Vasaturo F; Sallusti E; Gradilone A; Malacrino C; Nardo T; Avagnano G; Aglianò AM; Granato T; De Vincenzi B; Coppotelli G; Marzullo A; Soda G; Simonelli L; Modesti M; Scarpa S
Int J Oncol; 2005 Oct; 27(4):1005-11. PubMed ID: 16142317
[TBL] [Abstract][Full Text] [Related]
23. Localization of p53 and proliferating cell nuclear antigen in fine-needle aspirates of benign and primary malignant tumors of the human breast: an immunocytochemical study using supersensitive monoclonal antibodies and the biotin-streptavidin-amplified method.
Alexiev BA
Diagn Cytopathol; 1996 Nov; 15(4):277-81. PubMed ID: 8982580
[TBL] [Abstract][Full Text] [Related]
24. [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient].
Li BJ; Wang JY; Wang HY; Huang XP; Zhang LJ; Long H; Yang MT; Rong TH
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):766-9. PubMed ID: 17366790
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1.
Kreipe H; Alm P; Olsson H; Hauberg M; Fischer L; Parwaresch R
Am J Pathol; 1993 Feb; 142(2):651-7. PubMed ID: 8094598
[TBL] [Abstract][Full Text] [Related]
26. S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast.
Schor AP; Carvalho FM; Kemp C; Silva ID; Russo J
Oncol Rep; 2006 Jan; 15(1):3-6. PubMed ID: 16328027
[TBL] [Abstract][Full Text] [Related]
27. Correspondence Re: WM Hanna, Kahn HJ, and J-AW Chapman. The correlation of Ki-67 growth factor and ERICA in breast cancer. Mod Pathol 5:220, 1992.
Heatley M; Whiteside C; Maxwell P; Toner PG
Mod Pathol; 1994 Oct; 7(8):889-90. PubMed ID: 7838848
[No Abstract] [Full Text] [Related]
28. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
Ciampa A; Fanger G; Khan A; Rock KL; Xu B
Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
[TBL] [Abstract][Full Text] [Related]
29. [Immunohistochemical evidence of vimentin in fibrocystic breast disease and mammary carcinoma].
Alexiev B; Valkov I; Popov A
Zentralbl Pathol; 1992 Sep; 138(4):284-8. PubMed ID: 1329942
[TBL] [Abstract][Full Text] [Related]
30. Cytological analysis and immunocytochemical expression of Ki67 and Bcl-2 in breast proliferative lesions.
Midulla C; Pisani T; De Iorio P; Cenci M; Divizia E; Nofroni I; Vecchione A
Anticancer Res; 2002; 22(2B):1341-5. PubMed ID: 12168948
[TBL] [Abstract][Full Text] [Related]
31. [Significance of proliferative breast lesions around breast cancers].
Moriya T; Manabe T; Sakurai T; Sakamoto K
Gan To Kagaku Ryoho; 1995 Apr; 22 Suppl 1():42-5. PubMed ID: 7747991
[TBL] [Abstract][Full Text] [Related]
32. [Benign and premalignant breast lesions--clinico-pathological correlation].
Afek A; Shibi R; Kopolovitz G
Harefuah; 1997 Nov; 133(9):375-8. PubMed ID: 9418343
[No Abstract] [Full Text] [Related]
33. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast.
Brown LF; Guidi AJ; Schnitt SJ; Van De Water L; Iruela-Arispe ML; Yeo TK; Tognazzi K; Dvorak HF
Clin Cancer Res; 1999 May; 5(5):1041-56. PubMed ID: 10353737
[TBL] [Abstract][Full Text] [Related]
34. Toker cells are probably precursors of Paget cell carcinoma: a morphological and ultrastructural description.
Marucci G; Betts CM; Golouh R; Peterse JL; Foschini MP; Eusebi V
Virchows Arch; 2002 Aug; 441(2):117-23. PubMed ID: 12189500
[TBL] [Abstract][Full Text] [Related]
35. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
36. Multinucleated stromal giant cells in breast lesions.
Ryska A
Acta Cytol; 2003; 47(1):112-3. PubMed ID: 12585045
[No Abstract] [Full Text] [Related]
37. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas.
Iino K; Sasano H; Yabuki N; Oki Y; Kikuchi A; Yoshimi T; Nagura H
Mod Pathol; 1997 Sep; 10(9):901-7. PubMed ID: 9310953
[TBL] [Abstract][Full Text] [Related]
38. Proliferative activity in non-Hodgkin's lymphomas and chronic lymphocytic leukemias as determined on cytological samples by Ki 67 monoclonal antibody.
Musto P; Melillo L; Lombardi G; Aieta M; Di Renzo N; Carotenuto M
Haematologica; 1990; 75(6):583-4. PubMed ID: 2098303
[No Abstract] [Full Text] [Related]
39. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases.
Briffod M; Hacène K; Le Doussal V
Mod Pathol; 2000 Aug; 13(8):841-50. PubMed ID: 10955449
[TBL] [Abstract][Full Text] [Related]
40. C-erbB-2: expression in patients with breast carcinoma in comparison to patients with benign breast diseases.
Kalogeraki A; Tzardi M; Datseris G; Kanavaros P; Karvelas C; Chalkiadakis G; Tsiftsis D; Delides G
Anticancer Res; 1996; 16(2):765-71. PubMed ID: 8687126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
